207 related articles for article (PubMed ID: 17259801)
21. Pituitary gland: Medical therapy for acromegaly: can we predict response?
Giustina A; Porcelli T
Nat Rev Endocrinol; 2009 Aug; 5(8):425-7. PubMed ID: 19629067
[TBL] [Abstract][Full Text] [Related]
22. Medical Treatment of Acromegaly with Dopamine Agonists or Somatostatin Analogs.
Chanson P
Neuroendocrinology; 2016; 103(1):50-8. PubMed ID: 25677539
[TBL] [Abstract][Full Text] [Related]
23. Drug insight: Primary medical therapy of acromegaly.
Katznelson L
Nat Clin Pract Endocrinol Metab; 2006 Feb; 2(2):109-17; quiz following 117. PubMed ID: 16932265
[TBL] [Abstract][Full Text] [Related]
24. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
[TBL] [Abstract][Full Text] [Related]
25. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
Mattar P; Alves Martins MR; Abucham J
Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
[TBL] [Abstract][Full Text] [Related]
26. Place of cabergoline in acromegaly: a meta-analysis.
Sandret L; Maison P; Chanson P
J Clin Endocrinol Metab; 2011 May; 96(5):1327-35. PubMed ID: 21325455
[TBL] [Abstract][Full Text] [Related]
27. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
28. Newer options in the management of acromegaly.
Burt MG; Ho KK
Intern Med J; 2006 Jul; 36(7):437-44. PubMed ID: 16780450
[TBL] [Abstract][Full Text] [Related]
29. Management of acromegaly: is there a role for primary medical therapy?
Bush ZM; Vance ML
Rev Endocr Metab Disord; 2008 Mar; 9(1):83-94. PubMed ID: 18163213
[TBL] [Abstract][Full Text] [Related]
30. Current treatment guidelines for acromegaly.
Melmed S; Jackson I; Kleinberg D; Klibanski A
J Clin Endocrinol Metab; 1998 Aug; 83(8):2646-52. PubMed ID: 9709926
[TBL] [Abstract][Full Text] [Related]
31. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients.
Gatta B; Hau DH; Catargi B; Roger P; Tabarin A
Clin Endocrinol (Oxf); 2005 Oct; 63(4):477-8. PubMed ID: 16181243
[No Abstract] [Full Text] [Related]
32. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
33. The role of combination medical therapy in acromegaly: hope for the nonresponsive patient.
Fleseriu M
Curr Opin Endocrinol Diabetes Obes; 2013 Aug; 20(4):321-9. PubMed ID: 23807604
[TBL] [Abstract][Full Text] [Related]
34. Cabergoline treatment of acromegaly: a preliminary dose finding study.
Jackson SN; Fowler J; Howlett TA
Clin Endocrinol (Oxf); 1997 Jun; 46(6):745-9. PubMed ID: 9274706
[TBL] [Abstract][Full Text] [Related]
35. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
Cozzi R; Attanasio R; Barausse M; Dallabonzana D; Orlandi P; Da Re N; Branca V; Oppizzi G; Gelli D
Eur J Endocrinol; 1998 Nov; 139(5):516-21. PubMed ID: 9849816
[TBL] [Abstract][Full Text] [Related]
36. Treatment of acromegaly.
Holdaway IM
Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805
[TBL] [Abstract][Full Text] [Related]
37. [The 10-minute office visit. Untreated acromegaly shortens life expectancy. You must be able to state the suspected diagnosis].
Biering H; Strasburger CJ
MMW Fortschr Med; 2005 Apr; 147(14):55-6. PubMed ID: 15887688
[No Abstract] [Full Text] [Related]
38. An update on treatment strategies for acromegaly.
Katznelson L
Expert Opin Pharmacother; 2008 Sep; 9(13):2273-80. PubMed ID: 18710352
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Ciresi A; Radellini S; Guarnotta V; Giordano C
BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
